Adaptive Biotechnologies Corp (ADPT)vsJohnson & Johnson (JNJ)
ADPT
Adaptive Biotechnologies Corp
$28.37
+2.57%
HEALTHCARE · Cap: $3.83B
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 32143% more annual revenue ($99.33B vs $308.08M). JNJ leads profitability with a 16.2% profit margin vs -20.7%. JNJ earns a higher WallStSmart Score of 57/100 (C).
ADPT
Avoid28
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.4%
Fair Value
$31.48
Current Price
$28.37
$3.11 discount
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.5% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
0.0% earnings growth
Trading at 31.5x book value
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : ADPT
The primary concerns for ADPT are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 2.87 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ADPT profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.10 — expect wider price swings.
ADPT is growing revenue faster at 21.5% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 28/100), backed by strong 16.2% margins. ADPT offers better value entry with a 50.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?